Before psychedelics were prohibited, clinical research with complex psychiatric patients developed diverse treatment methods and practices that remain relevant today. These early studies, though lacking modern rigor, recognized that the treatment context and clinician's role are essential for positive outcomes. This review examines pre-prohibition clinical narratives about the phenomenology of psychedelic treatment and non-pharmacological factors in patient experience. It also explores clinician perspectives and psychological interventions from that era to inform future research directions and best practice guidelines for modern psychedelic research and clinician training.
Psychedelic therapy, which uses compounds like psilocybin to treat psychiatric disorders, works through serotonergic modulation and 5-HT2A receptor activation, inducing neuroplasticity and altered consciousness. Its therapeutic potential extends beyond biochemical effects, as structured therapy—including preparation, administration, and integration—produces enduring changes in self-perception, emotion regulation, and interpersonal connectedness. This paper argues that psychedelics offer a fundamentally different therapeutic model requiring a reconceptualization of mental health treatment, integrating neuroscientific findings with phenomenological insights. Further research is needed to refine protocols and understand the link between subjective experiences and outcomes.